This specific card is a rare promo stamp reverse holo version, with the stamp indicating it was released at a Pokémon League event. The card is of Canadian origin and is a valuable addition for collectors of Pokémon TCG cards.
The card stock is printed on a bright white base, making the art look crisp.
To continue please click the link below.
To continue please click the link below.
To continue please click the link below.
Luigi Longinotti is Managing Director and General Manager for EMEA at Recordati Rare Diseases, leading the European and Middle Eastern Commercial Operations. He is responsible for Marketing, Medical, Market Access, Regulatory, Manufacturing and Logistics, as well as the enabling functions to support the business, including Compliance and Quality.
He joined Recordati in July 2014 as Corporate Portfolio Management Director for Orphan Drugs. In such a role he has been responsible for driving the growth of the rare disease portfolio at Recordati, with his duties ranging from business development to strategic marketing and pipeline project management.
Before he joined Recordati, he held senior business and corporate development roles at Chiesi Farmaceutici and Menarini Group where he executed several key asset deals and transactions.
Luigi gained a degree in Economics from the University of Florence and a Master’s degree in Business Innovation from Sant’Anna School of Advanced Studies in Pisa.
Bruno Parenti is Head of LAC Region at Recordati Rare Diseases, leading the business in Latin America, Asia Pacific and Russia. He has been in this position since 2011, where he spearheaded the expansion of operations around the globe. He recently assumed the additional role of Head of Global Endocrinology Franchise, establishing the new HQ in Basel and building a dedicated organization.
Prior to these positions, Bruno spent two years at Recordati Ireland overseeing international sales in the Asia-Pacific region. He served at Chiesi Farmaceutici for two years as Area Manager for the Far East. Earlier in his career, he held commercial roles at Kedrion Biopharmaceuticals where he was responsible for international markets with a focus on Latin America and the Middle East.
Scott Pescatore is Vice President and Head of Global Operations at Recordati Rare Diseases.
He holds a Doctor of Pharmacy degree and completed his post-doctoral fellowship in Pharmacology and Drug Development. Dr Pescatore has spent over 20 years working internationally in the pharmaceutical industry, specializing in oncology, haematology and rare diseases.
He joined Novartis Oncology US in 2001 where he served in various medical, sales and marketing roles of increasing responsibility. In 2008, he moved to Novartis Oncology UK as Business Franchise Head for solid tumours where he also managed the New Products portfolio. In 2010 he moved to Milan to manage the Region Europe Haematology Franchise where he led the joint venture between Novartis Oncology and Incyte to launch a novel treatment for myeloproliferative disorders. In 2014 he was appointed the Oncology General Manager in Ireland and after three years returned to Milan as General Manager of the Region Europe Rare Disease Business Unit, overseeing operations in 37 markets and focusing on the endocrinology portfolio.
Prior to joining Recordati Rare Diseases in 2020, he was Vice President Oncology Business Unit for AstraZeneca Italy where he was responsible for the portfolio of oncology/haematology products including two joint ventures with MSD and Daiichi Sankyo.
To continue please click the link below.